

Claims

1. Composition comprising myo-inositol for use in the prevention of preterm birth and/or of conditions linked to preterm birth in a female subject and/or in the offspring.
2. Composition for use in accordance with claim 1, wherein the composition further comprises probiotics.
3. Composition for use in accordance with claim 2, wherein the probiotics comprise a combination of Lactobacillus and Bifidobacterium.
4. Composition for use in accordance with claim 3, wherein the Lactobacillus is the Lactobacillus rhamnosus GG strain available under the deposit number CGMCC 1.3724, and the Bifidobacterium is the Bifidobacterium lactis BB12 strain deposited as CNCM I-3446.
5. Composition for use in accordance with one of the preceding claims, wherein the composition further comprises at least one vitamin selected from the group consisting of vitamin B2, vitamin B6, vitamin B12, vitamin D and mixtures thereof.
6. Composition for use in accordance with one of the preceding claims, wherein the composition comprises myo-inositol, vitamin B2, vitamin B6, vitamin B12, vitamin D, a Bifidobacterium lactis BB12 CNCMI-3446 and a Lactobacillus rhamnosus GG CGMCC 1.3724.

7. Composition for use in accordance with one of the preceding claims, wherein the composition comprises 0.2 to 5 g of myo-inositol, from 0.14 to 14 mg of vitamin B2, from 0.19 to 19 mg of vitamin B6, from 0.26 to 26 µg of vitamin B12, from 1.5 to 100 µg of vitamin D, from 10^5 to 10^{12} cfu of Bifidobacterium lactis BB12 CNCMI-3446 and a from 10^5 to 10^{12} cfu of Lactobacillus rhamnosus GG CGMCC 1.3724, all amounts being defined by daily dose.

8. Composition for use in accordance with one of the preceding claims, wherein the composition further comprises zinc.

9. Composition for use in accordance with one of the preceding claims, wherein the disorder and/or condition linked to preterm birth in the offspring is selected from the group consisting of increased risks of neonatal respiratory conditions (such as respiratory distress syndrome and bronchopulmonary dysplasia), necrotizing enterocolitis, sepsis, neurological conditions (such as periventricular leukomalacia, seizures, intraventricular hemorrhage, cerebral palsy, and hypoxic ischemic encephalopathy), feeding difficulties, visual and hearing problems, poor neurodevelopmental outcomes, high rates of hospital admissions, behavioral, social-emotional, and learning difficulties in childhood, increased risks of hypertension later in life, cardiovascular and cerebrovascular diseases later in life, type 2 diabetes later in life, chronic kidney disease later in life, asthma and abnormalities in pulmonary function, neurocognitive disorder and combinations thereof; or wherein the disorder and/or condition linked to preterm birth in the female subject is an increased risk of maternal mortality.

10. Composition for use in accordance with one of the preceding claims, wherein the subject is a mammal, for example selected from the group consisting of a cat, a dog and a human.

11. Composition for use in accordance with one of the preceding claims, wherein the subject is a female who is trying to get pregnant or is pregnant.

5 12. Composition for use in accordance with one of the preceding claims, wherein the composition is to be administered to a subject at risk of premature delivery.

10 13. Composition for use in accordance with one of the preceding claims, wherein the composition is to be administered to a subject during pregnancy, for example during throughout the second and third trimesters of pregnancy.

15 14. Composition for use in accordance with one of the preceding claims, wherein the composition is in the form of a powdered nutritional composition to be reconstituted in milk or water, a food product, a drink, a nutritional supplement or a nutraceutical.

20 15. A kit of parts comprising at least two physically separated compositions, each comprising at least one ingredient selected from the group consisting of from vitamin B2, vitamin B6, vitamin B12, and vitamin D, at least one of the physically separated compositions comprises myo-inositol and at least one of the physically separated compositions comprises probiotics, for use in the prevention of preterm delivery and/or conditions linked to preterm delivery in a female subject and/or in the offspring.

25